Chemo combo boosts survival in advanced prostate cancer
Disease control
Completed
This large phase 3 trial tested whether adding the chemotherapy drug docetaxel to standard hormone therapy helps men with metastatic prostate cancer live longer. 790 men participated. The results showed that the combination improved overall survival compared to hormone therapy al…
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC